New treatments for pattern hair loss are driving a surge in biotech stock valuations as Wall Street targets the condition as an untapped consumer market. How New Hair Loss Drug Stocks Are Surging The promise of novel treatments has driven substantial market gains for pharmaceutical developers. Meanwhile, Absci stock has more than doubled throughout the … Read more
Experimental biotech pill ENV-308 delivers an encouraging safety profile in a Phase 1 clinical trial of 88 healthy adults, according to startup biotech company Enveda. Designed to curb appetite by mimicking the body’s natural response to vigorous exercise, the daily oral tablet replicates a molecule discovered by Stanford scientists in 2022 without triggering the gastrointestinal … Read more
According to research from the Pennington Biomedical Research Center, patients taking GLP-1 receptor agonists for weight loss are experiencing unexpected medical benefits beyond fat reduction, including decreased cravings for alcohol and reduced joint inflammation. Dr. Steven Heymsfield, a professor and director of the Metabolism Body Composition Laboratory at Pennington, states that while clinical trials predicted … Read more
The medical practice of using donated human cadaver fat—colloquially termed “zombie filler”—is gaining traction in cosmetic surgery as a solution for patients experiencing rapid weight loss. According to Dr. Anthony Rossi, a New York-based dermatologist and surgeon, the procedure involves injecting processed fat from deceased donors into areas like the face, arms, or buttocks, a … Read more
Chrissy Metz Discloses GLP-1 Use Amid Shift in Weight Management Approach "This Is Us" actress Chrissy Metz has begun using GLP-1 medication to assist with her health journey, citing long-term struggles with weight and persistent "food noise." Metz, 45, is partnering with the telehealth company Ro to manage her treatment, marking a departure from her … Read more
Eli Lilly reported second-quarter revenue of $23 billion, a 48% increase year over year, driven by soaring demand for its GLP-1 medications Mounjaro and Zepbound, according to the company’s earnings report. The pharmaceutical giant subsequently raised its annual revenue guidance to a range between $85 billion and $87 billion, pushing its stock price up nearly … Read more
The Department of Veterans Affairs is launching a nationwide clinical trial to determine whether semaglutide can help treat alcohol use disorder, a condition officially diagnosed in more than 400,000 veterans nationwide, according to department data. VA researchers are studying the GLP-1 receptor agonist—marketed as Ozempic for Type 2 diabetes and Wegovy for chronic weight management—to … Read more
According to a clinical study published in Obesity Pillars, participants taking the dietary supplement Calocurb lost an average of 8.3 pounds over 24 weeks while maintaining lean muscle mass. The findings arrive as consumers and researchers increasingly scrutinize popular GLP-1 weight loss treatments for causing significant reductions in lean muscle alongside fat loss. Understanding Calocurb … Read more
Calocurb, a New Zealand-based company, has announced findings from a new clinical study published in the US medical journal Obesity Pillars. According to the brand, the research demonstrates that its 100% natural GLP-1 activator effectively promotes weight loss while preserving muscle mass during six months of consistent use paired with a healthy diet and exercise. … Read more
The prevalence of GLP-1 drugs for weight loss among U.S. adults has reached a record high, with 11% of the population currently using medications like Ozempic and Wegovy, according to a Gallup survey of 5,065 adults conducted between May 28 and June 5. This surge correlates with a decline in the national obesity rate, which … Read more